@article {12504, title = {Estimated wasteful spending on aducanumab dispensing in the U.S. Medicare population: A cross-sectional analysis.}, journal = {Journal of the American Geriatrics Society}, volume = {70}, year = {2022}, pages = {2714-2718}, abstract = {Aducanumab, a weight-dosed Alzheimer{\textquoteright}s drug with uncertain benefits and high cost, could strain Medicare{\textquoteright}s budget if approved for widespread use.1 In April 2022, Medicare issued a final determination restricting aducanumab{\textquoteright}s use to clinical trials. However, Medicare{\textquoteright}s coverage decision may still be overturned by legal challenges, potentially leading to much higher uptake.2 Moreover, several other Alzheimer{\textquoteright}s infusion drugs similar to aducanumab are currently in the development pipeline.3 Because aducanumab is available in two fixed-dose vial sizes, its use may result in large amounts of discarded drug and wasteful spending.4, 5 To quantify the amount of discarded drug and potential savings that could be generated from more efficient aducanumab vial sizes, we analyzed patient weight distributions from a nationally representative sample of Medicare beneficiaries with mild cognitive impairment (MCI) or mild dementia. }, keywords = {Alzheimer disease, drugs, Medicare, Spending}, issn = {1532-5415}, doi = {10.1111/jgs.17891}, author = {Oronce, Carlos Irwin A and Arbanas, Julia Cave and Leng, Mei and Landon, Bruce E and Damberg, Cheryl L and Sarkisian, Catherine and Mafi, John N} }